JP2009532399A - 多発性硬化症および／または関節リウマチの処置 - Google Patents

多発性硬化症および／または関節リウマチの処置 Download PDF

Info

Publication number
JP2009532399A
JP2009532399A JP2009503466A JP2009503466A JP2009532399A JP 2009532399 A JP2009532399 A JP 2009532399A JP 2009503466 A JP2009503466 A JP 2009503466A JP 2009503466 A JP2009503466 A JP 2009503466A JP 2009532399 A JP2009532399 A JP 2009532399A
Authority
JP
Japan
Prior art keywords
antibody
treatment
medicament
ccr2
multiple sclerosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009503466A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009532399A5 (https=
Inventor
マルコ・プリンツ
ヴォルフガング・ブリュック
アレクサンダー・ミルトナー
マティアス・マック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaetsmedizin Goettingen Georg August Universitaet
Universitätsklinikum Regensburg
Original Assignee
Universitaetsmedizin Goettingen Georg August Universitaet
Universitätsklinikum Regensburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaetsmedizin Goettingen Georg August Universitaet, Universitätsklinikum Regensburg filed Critical Universitaetsmedizin Goettingen Georg August Universitaet
Publication of JP2009532399A publication Critical patent/JP2009532399A/ja
Publication of JP2009532399A5 publication Critical patent/JP2009532399A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2009503466A 2006-04-03 2007-04-02 多発性硬化症および／または関節リウマチの処置 Pending JP2009532399A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006015341A DE102006015341A1 (de) 2006-04-03 2006-04-03 Behandlung von multipler Sklerose und/oder rheumatoider Arthritis
PCT/EP2007/002929 WO2007115713A1 (de) 2006-04-03 2007-04-02 Behandlung von multipler sklerose und/oder rheumatoider arthritis

Publications (2)

Publication Number Publication Date
JP2009532399A true JP2009532399A (ja) 2009-09-10
JP2009532399A5 JP2009532399A5 (https=) 2012-12-13

Family

ID=38226352

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009503466A Pending JP2009532399A (ja) 2006-04-03 2007-04-02 多発性硬化症および／または関節リウマチの処置

Country Status (8)

Country Link
US (1) US9068002B2 (https=)
EP (2) EP2004692B1 (https=)
JP (1) JP2009532399A (https=)
CN (1) CN101466735A (https=)
AU (1) AU2007236269B2 (https=)
CA (1) CA2648330C (https=)
DE (1) DE102006015341A1 (https=)
WO (1) WO2007115713A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020517256A (ja) * 2017-04-19 2020-06-18 エルスター セラピューティクス， インコーポレイテッド 多重特異性分子およびその使用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013276991C1 (en) * 2007-08-13 2016-08-11 Takeda Pharmaceutical Company Limited IVIG Modulations of Chemokines for Treatment of Multiple Sclerosis, Alzheimer's Disease, and Parkinson's Disease
EP2727944A1 (en) * 2012-10-30 2014-05-07 Universitätsklinikum Regensburg Depletion of CCR2-positive monocytes for the treatment of inflammatory conditions in the gastrointestinal system
WO2020232127A1 (en) * 2019-05-13 2020-11-19 The Research Foundation For The State University Of New York Compositions and methods to block and bind ccr2 to modulate cellular function
IL302390A (en) 2020-11-09 2023-06-01 Takeda Pharmaceuticals Co Drug antibody conjugates
MX2024004447A (es) 2021-10-27 2024-05-08 Granite Bio Ag Anticuerpos dirigidos a ccr2.
CN121399160A (zh) 2023-05-29 2026-01-23 花岗岩生物股份公司 靶向ccr2的抗体

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000510685A (ja) * 1996-03-01 2000-08-22 コンセジョ スペリオール デ インベスティガシオネス サイエンティフィカス 単球化学誘引タンパク質１（ｍｃｐ―１）レセプター（ｃｃｒ２）に結合する抗体
JP2002521021A (ja) * 1998-07-23 2002-07-16 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 抗−ｃｃｒ２抗体及びその使用方法
JP2003521927A (ja) * 2000-02-03 2003-07-22 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ヒト化抗ｃｃｒ−２抗体およびその使用方法
WO2005060368A2 (en) * 2003-12-10 2005-07-07 Millennium Pharmaceuticals, Inc. Humanized anti-ccr2 antibodies and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6696550B2 (en) * 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
US6723538B2 (en) * 1999-03-11 2004-04-20 Micromet Ag Bispecific antibody and chemokine receptor constructs
SE0002045D0 (sv) 2000-05-31 2000-05-31 Sahltech Ab New use
US20040151721A1 (en) 2001-10-19 2004-08-05 O'keefe Theresa Humanized anti-CCR2 antibodies and methods of use therefor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000510685A (ja) * 1996-03-01 2000-08-22 コンセジョ スペリオール デ インベスティガシオネス サイエンティフィカス 単球化学誘引タンパク質１（ｍｃｐ―１）レセプター（ｃｃｒ２）に結合する抗体
JP2002521021A (ja) * 1998-07-23 2002-07-16 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 抗−ｃｃｒ２抗体及びその使用方法
JP2003521927A (ja) * 2000-02-03 2003-07-22 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ヒト化抗ｃｃｒ−２抗体およびその使用方法
WO2005060368A2 (en) * 2003-12-10 2005-07-07 Millennium Pharmaceuticals, Inc. Humanized anti-ccr2 antibodies and methods of use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN5009003130; ＢＲＵＥＨＬ　ＨＩＬＫＥ: ＪＯＵＲＮＡＬ　ＯＦ　ＩＭＭＵＮＯＬＯＧＹ Ｖ１７２　Ｎ２, 200401, Ｐ８９０-８９８ *
JPN5009003133; ＢＲＵＥＨＬ，　Ｈ．: ＺＥＩＴＳＣＨＲＩＦＴ　ＦＵＥＲ　ＲＨＥＵＭＡＴＯＬＯＧＩＥ Ｖ６５　ＳＵＰＰＬ．１, 2006 *
JPN5009003135; ＢＲＯＤＭＥＲＫＥＬ　ＣＡＲＲＩＥ　Ｍ: ＪＯＵＲＮＡＬ　ＯＦ　ＩＭＭＵＮＯＬＯＧＹ Ｖ１７５　Ｎ８, 200510, Ｐ５３７０-５３７８ *
JPN6013009118; ＥＬ-ＡＳＭＡＲ，Ｌ．　ｅｔ　ａｌ: 'Ｅｖｉｄｅｎｃｅ　ｆｏｒ　ｎｅｇａｔｉｖｅ　ｂｉｎｄｉｎｇ　ｃｏｏｐｅｒａｔｉｖｉｔｙ　ｗｉｔｈｉｎ　ＣＣＲ５-ＣＣＲ２ｂ　ｈｅｔｅｒｏｄｉｍｅｒｓ' Ｍｏｌ　Ｐｈａｒｍａｃｏｌ Ｖｏｌ．６７，　Ｎｏ．２, 2005, ｐ．４６０-９ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020517256A (ja) * 2017-04-19 2020-06-18 エルスター セラピューティクス， インコーポレイテッド 多重特異性分子およびその使用
US12134654B2 (en) 2017-04-19 2024-11-05 Marengo Therapeutics, Inc. Multispecific molecules and uses thereof

Also Published As

Publication number Publication date
US20090311273A1 (en) 2009-12-17
CA2648330A1 (en) 2007-10-18
CA2648330C (en) 2015-11-24
CN101466735A (zh) 2009-06-24
EP2004692B1 (de) 2013-07-24
US9068002B2 (en) 2015-06-30
EP2481757A1 (de) 2012-08-01
WO2007115713A1 (de) 2007-10-18
EP2004692A1 (de) 2008-12-24
AU2007236269B2 (en) 2012-09-20
DE102006015341A1 (de) 2007-10-04
AU2007236269A1 (en) 2007-10-18

Similar Documents

Publication Publication Date Title
JP5693127B2 (ja) Ｎｋｇ２ｄの調節
TWI784988B (zh) 治療發炎症狀的方法
Brühl et al. Targeting of Gr‐1+, CCR2+ monocytes in collagen‐induced arthritis
JP5394916B2 (ja) Ｎｋｇ２ｄの調節方法
JP2009532399A (ja) 多発性硬化症および／または関節リウマチの処置
KR20140014392A (ko) 루푸스 치료 방법 및 조성물
EP3082863B1 (en) Alpha-enolase specific antibodies and method of use in immune diseases
JP5777522B2 (ja) 初期段階の関節リウマチ治療用のｉｌ−３阻害剤
US20140234307A1 (en) Method of treating multiple sclerosis by intrathecal depletion of b cells and biomarkers to select patients with progressive multiple sclerosis
JP2020100582A (ja) 多発性硬化症抑制剤
JP7576847B2 (ja) 免疫応答抑制剤

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100331

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120529

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120823

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120830

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120928

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121005

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20121029

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130305

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130516

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130523

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131105

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20140120